These rankings are based on data from December 2025
Company
Parallel Bio
Years in business
- 5
Number of employees
- 2-10 employees
Country
- United States
Parallel Bio uses populations of human immune organoids combined with AI to discover and de-risk immunotherapies. Their platform generates proprietary immune data at scale, enabling trial-in-a-dish safety prediction, advanced disease modeling, and target discovery. Verified candidates can be moved to market faster with reduced risk and cost.
API Availability
- Unknown
Pricing
unknown
Use
ai disease diagnosis
target discovery
Position of Parallel Bio on sub rankings
December 2025
AI disease diagnosis - Overall
15 out of 138
United States - Overall
2,601 out of 16,681
AI disease diagnosis - Overall
15 out of 138
United States - Overall
2,601 out of 16,681
Industries
health & sports
it
research & development
Company
Parallel Bio
Years in business
- 5
Number of employees
- 2-10 employees
Country
- United States